Demant's divested hearing implant business was unprofitable in H1

Oticon Medical, which hearing aid manufacturer Demant sold off to Cochlear in April, booked a deficit of DKK 107m (USD 14.6m) in the first half year of 2022.

Photo: Jens Dresling/Politiken/Ritzau Scanpix

In April, when hearing aid group Demant announced its intention to sell its 15-year-old Hearing Implants business, also known as Oticon Medical, to Australian Cochlear, no one knew whether the business leg was running a profit or a loss.

Demant was only willing to talk top-line figures at the time, but in Tuesday’s second quarterly report, the company finally revealed precise figures for how well the discontinued operation has performed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Further reading

Related articles

Latest news

See all jobs